First post_老虎社区_美港股上老虎

2021-12-20

First post 😉

Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693871074,"tweetId":"693871074","gmtCreate":1640008398750,"gmtModify":1640008479714,"author":{"id":3585001294737518,"idStr":"3585001294737518","authorId":3585001294737518,"authorIdStr":"3585001294737518","name":"Universe宇宙","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":130,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>First post 😉</p></body></html>","htmlText":"<html><head></head><body><p>First post 😉</p></body></html>","text":"First post 😉","highlighted":2,"essential":1,"paper":1,"likeSize":7,"commentSize":19,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693871074","repostId":1138448212,"repostType":4,"repost":{"id":"1138448212","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640008237,"share":"https://www.laohu8.com/m/news/1138448212?lang=&edition=full","pubTime":"2021-12-20 21:50","market":"us","language":"en","title":"Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1138448212","media":"Dow Jones","summary":"Summit Therapeutics Inc. shares fell nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy","content":"<p>Summit Therapeutics Inc. shares fell&nbsp;nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy study didn't meet its primary endpoint for superiority for the treatment of C. difficle infection.</p>\n<p><img src=\"https://static.tigerbbs.com/5780de0c9ef3f0248ec3fa67eaa2037e\" tg-width=\"703\" tg-height=\"593\" referrerpolicy=\"no-referrer\"></p>\n<p>The investigational drug, ridinilazole, resulted in a higher observed sustained clinicial response than the antibiotic vancomycin but not superiority, Summit said. Sustained clinical response is defined as clinical response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment, the company said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit Therapeutics Shares Fall nearly 30% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study \n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 21:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics Inc. shares fell&nbsp;nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy study didn't meet its primary endpoint for superiority for the treatment of C. difficle infection.</p>\n<p><img src=\"https://static.tigerbbs.com/5780de0c9ef3f0248ec3fa67eaa2037e\" tg-width=\"703\" tg-height=\"593\" referrerpolicy=\"no-referrer\"></p>\n<p>The investigational drug, ridinilazole, resulted in a higher observed sustained clinicial response than the antibiotic vancomycin but not superiority, Summit said. Sustained clinical response is defined as clinical response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment, the company said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138448212","content_text":"Summit Therapeutics Inc. shares fell nearly 30% to $3.5 after the company said its Phase 3 Ri-CoDIFy study didn't meet its primary endpoint for superiority for the treatment of C. difficle infection.\n\nThe investigational drug, ridinilazole, resulted in a higher observed sustained clinicial response than the antibiotic vancomycin but not superiority, Summit said. Sustained clinical response is defined as clinical response of the treated episode of CDI and no recurrence of the infection through 30 days after the end of treatment, the company said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":327,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693871074"}